Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Payables (2016 - 2025)

Spero Therapeutics' Payables history spans 10 years, with the latest figure at $693000.0 for Q4 2025.

  • For Q4 2025, Payables fell 90.51% year-over-year to $693000.0; the TTM value through Dec 2025 reached $693000.0, down 90.51%, while the annual FY2025 figure was $693000.0, 90.51% down from the prior year.
  • Payables reached $693000.0 in Q4 2025 per SPRO's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.3 million in Q4 2024 to a low of $583000.0 in Q1 2023.
  • Average Payables over 5 years is $2.4 million, with a median of $1.7 million recorded in 2021.
  • Peak YoY movement for Payables: soared 452.13% in 2024, then tumbled 90.51% in 2025.
  • A 5-year view of Payables shows it stood at $1.1 million in 2021, then plummeted by 43.96% to $617000.0 in 2022, then surged by 123.34% to $1.4 million in 2023, then soared by 430.19% to $7.3 million in 2024, then tumbled by 90.51% to $693000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Payables are $693000.0 (Q4 2025), $1.4 million (Q3 2025), and $780000.0 (Q2 2025).